IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
IP Explained: Why IP protections are important for biologic medicines
By Tom Wilbur | July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...
Read More
PhRMA member companies invested nearly $80 billion in R&D last year
By Tim McClung | July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
"If Washington isn’t careful, we might leave innovation behind"
By Robert Zirkelbach | June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate...
Read More
New report finds 15 new oncology therapies launched last year
By Holly Campbell | June 5, 2019
A record 15 new oncology therapeutics launched in 2018 for 17 tumor types, according to IQVIA’s “Global Oncology Trends 2019” report. This progress includes a continued shift toward precision...
Read More
Guest Post: Using the patient voice to go boldly
By Guest Contributor | May 30, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals
By Tim McClung | May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
